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Abstract
Background: Hypoxia-inducible factor-1 (HIF-1) is a master regulator of the transcriptional response to hypoxia. It is
essential for angiogenesis and is associated with tumor progression and overexpression of HIF-1a has been
demonstrated in many common human cancers. Therefore, HIF-1a is one of the most compelling anticancer
targets.
Methods: To identify HIF-1a inhibitors, luciferase reporter gene assay under hypoxia and normoxia was used.
Detailed studies such as western blotting, RT-PCR, immunofluorescence were carried out to elucidate its
mechanism of action. Antiangiogenic activity of P3155 was demonstrated by migration assay and tube formation
assay. Efficacy study of P3155 was performed on PC-3 xenograft model.
Results: P3155 showed specific HIF-1a inhibition with IC50 of 1.4 μM under hypoxia. It suppressed HIF-1a
expression as well as PI3K/Akt pathway and abrogated expression of HIF-1-inducible gene viz. vascular endothelial
growth factor (VEGF). P3155 in combination with HIF-1a siRNA showed significant synergistic effect. In addition, it
demonstrated significant in vivo efficacy and antiangiogenic potential in prostate cancer cell lines.
Conclusion: We have identified a novel HIF-1a inhibitor P3155 that also modulates PI3K/Akt pathway, which may
contribute to its significant in vitro and in vivo antitumor activity.
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Background
Hypoxia is a common phenomenon in rapidly growing
solid tumors, and an important microenvironmental fac-
tor that contributes to the development of more malig-
nant phenotypes [1,2]. It triggers adaptive responses in
solid tumors that include induction of angiogenesis and
a switch to anaerobic metabolism [3]. Cells adapt to
hypoxia by down-regulating oxygen- and energy-depen-
dent processes, such as mRNA translation or protein
synthesis [4] while simultaneously up-regulating specific
genes that promote angiogenesis and stress survival.
HIF-1 is a heterodimeric protein and is composed of
oxygen sensitive HIF-1a and constitutively expressed
HIF-1b/ARNT subunit. Under nonhypoxic conditions,
HIF-1a protein is rapidly and continuously degraded by
ubiquitination and proteasomal degradation. Degrada-
tion of HIF-1a is dependent on binding with von Hip-
pel-Lindau and hydroxylation of Pro-564 via an
enzymatic process that requires O2 and iron [5,6]. How-
ever, under hypoxic conditions, prolyl hydroxylases
become inactivated, and thus, HIF-1a is stabilized and
HIF-1 activated.
In many human tumors, HIF-1a has been found to be
highly expressed due to hypoxia or when oncogenes or
tumor suppressor genes are mutated. Immunohistochem-
ical analyses show that HIF-1a is present at higher levels
in human tumors than in normal tissues [7]. Furthermore,
a correlation between HIF-1a overexpression and
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poor patient prognosis has been observed [8]. Moreover,
tumor growth and angiogenesis in xenograft tumors also
depends on HIF-1 activity and on the HIF-1a expression
[9]. Thus, HIF-1a is viewed as an excellent target for the
development of novel cancer therapeutics [10].
Recently we focused our efforts on the development of
novel inhibitors of HIF-1a We screened for small mole-
cules to find inhibitors of HIF accumulation under
hypoxic condition. In our quest for finding potential
therapeutics, we used pyridylpyrimidine as a basic scaf-
fold; various molecules were designed, synthesized and
characterized. Out of these molecules, P3155 and P2630
were identified as potent and specific HIF-1a inhibitors
in the reporter gene-based assay [ref [11]- structure 7
and 4a respectively]. Herein, we report the anticancer
activity and mechanism of action of P3155.
Methods
Cell culture
Human prostate cancer cell lines PC-3 and DU145 were
cultured in RPMI-1640 containing 10% fetal bovine serum
(FBS) (Hyclone, UT, USA), 2 mmol/L L-glutamine
(Gibco, Grand Island, NY, USA), 100 U/ml penicillin and
100 mg/ml streptomycin (Gibco). Human umbilical vein
endothelial cells (HUVECs) were obtained from Cascade
Biologics (Oregon, USA) and were cultured in M-200
medium (Cascade Biologics) supplemented with low
serum growth supplements (LSGS) (Cascade Biologics),
penicillin-G (100 U/ml), streptomycin (100 μg/ml) and
amphotericin B (50 ng/ml) (Gibco). The cell lines were
maintained in a humidified incubator at 37°C and 5%
CO2. Topotecan was purchased from Calbiochem. P3155
was synthesized at Piramal Life Sciences Ltd., Mumbai,
India. Both the compounds were dissolved in dimethyl
sulfoxide (DMSO) at a concentration of 10 mmol/L (10
mM) and stored at -20°C until use; were diluted in culture
medium RPMI-1640 immediately before use and was used
within 4 h. All reagents were purchased from Sigma Che-
mical (St Louis, MO, USA) unless otherwise mentioned.
Luciferase Reporter assay
U251-HRE and U251-pGL3 cell lines were procured
from Dr. Giovanni’s Lab and maintained as described by
Rapisarda et al previously [12]. Luciferase reporter gene
assay was carried out using both these cell lines as
described previously in detail [12]. Data was analyzed to
determine the EC50 concentration (concentration of
compound that inhibited luciferase expression by 50%).
Western blot analysis
PC-3 cells were used for western blot analysis as
described earlier [13]. Compounds were added accord-
ing to concentrations and desferoxamine (DFX) (hypoxia
mimick) at a final concentration of 60 μmol/L was
added to each of the plates except the control (no DFX)
plate. The plates were then incubated in a humidified
incubator (5% CO2) for 8 h and then harvested. The
antibodies used were anti-HIF-1a monoclonal antibody
( B DB i o s c i e n c e s ,C A ) ,a n t i - p - A k t 4 7 3 ,a n t i - p - 4 E - B P 1
antibody (Cell Signaling Technology) or anti-b-actin
antibody (Sigma).
Reverse transcription-PCR
For RT-PCR analysis, total cellular RNA was isolated
with TRI reagent (Sigma, USA). cDNA synthesis was car-
ried out and PCR was performed on cDNA with 2× PCR
master mix (Fermentas, USA) and the corresponding pri-
mers. The following primers were used-HIF-1a Forward
primer TATGACCTGCTTGGTGCTGA Reverse primer
GGGAGAAAATCAAGTCGTGC annealing temperature
of 60°C and cycle no. 32. Tubulin: Forward primer
TCTGTTCGCTCAGGTCCTTTTGGCC Reverse primer
CGTACCACATCCAGGACAGA annealing temperature
of 55°C and cycle no. 30. VEGF Forward primer
AACTTTCTGCTGTCTTGG Reverse primer TTTGGT
CTGCATTCACAT annealing temperature 55°C cycle
no. 35. An aliquot of each reaction mixture was analyzed
by electrophoresis on a 1.5% agarose gel and the gel
images were obtained using Quantity one software (Bio
Rad, USA).
Immunofluorescence
Cells (0.3 × 10
6) were seeded onto poly-D-lysine coated
glass coverslips and incubated overnight. Cells were
untreated or exposed to 60 μmol/L DFX for 8 h, in the
absence or presence of different concentrations of
P3155 and processed for immunofluorescence staining
as described earlier [14]. The antibodies used were:
mouse monoclonal anti-HIF-1a antibody (BD Transduc-
tion Labs, CA, USA), rabbit polyclonal anti-VEGF anti-
body (Santa Cruz Biotechnology, CA, USA), FITC-
conjugated anti-mouse antibody, Cy3-conjugated anti-
rabbit antibody (Chemicon International, USA). Images
were captured using fluorescent microscope.
SiRNA mediated RNA interference
Cells were plated in 6 well plates in FBS-free and anti-
biotic-free media. The cells were transiently transfected
with siRNA (HIF-1a-specific siRNA or non-specific
siRNA, QIAGEN, USA) using Lipofectamine2000 Trans-
fection Reagent (Invitrogen, Carlsbad, CA) and allowed
to stabilize for 24 h, before being used in experiments.
Migration assay
Cells were seeded at a density of (0.5 - 2.0) × 10
6 per
well in a sterile 6 well plate. The plates were incubated
overnight in humidified CO2 incubator (5% CO2)a t3 7 °
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Page 2 of 10C under ambient oxygen levels for the cells to form a
confluent uniform monolayer on the complete surface
of the well. The cell monolayer was scraped to create a
“scratch” with a pipette tip and the first image of the
scratches was acquired. Compounds were added at var-
ious concentrations and the plates were further incu-
bated for 24 h. After the incubation, the plate was
placed under a phase contrast microscope, reference
point was matched, the photographed regions of the
f i r s ti m a g ew e r ea l i g n e da n dt h es e c o n di m a g ew a s
acquired.
3D Gel Endothelial Tube formation assay
The BD Matrigel Matrix (BD Biosciences, USA) was
thawed at 4°C overnight on ice. HUVEC endothelial
cells were cultured to 60-80% confluence. Endothelial
cell suspensions were prepared by trypsinizing the
monolayers and resuspending the cells in culture med-
ium with 5-10% serum (used as an angiogenesis promo-
ter). 0.5 - 1 × 10
6 cells per 180 μl were added (per well
of 24 well plate) of thawed BD Matrigel Matrix. The
cells were allowed to adhere for 2-3 h. Subsequently, the
compounds were added at appropriate concentrations to
the respective wells. Appropriate control (medium con-
trol) was employed. Following 24 - 48 h of incubation,
the cells were observed under the microscope for tube
formation and angiogenesis.
In vivo studies
The human prostate cancer cells (PC-3) were grown and
harvested. Cells were resuspended in saline at 10 million
cells/0.2 mL volume and placed on ice. Severe combined
immunodeficient mice were injected in 0.2 mL volume
s.c. on the right flank and observed daily for tumor
appearance. When the tumors attained a diameter of 5
mm, they were randomized into two groups. For control
(group I), water was administered every day p.o. for 20
days and, 50 mg/kg P3155 (group II), P3155 solution in
water was administered every day p.o. also for 20 days.
Statistical analysis
Statistical comparison was made using GraphPad
PRISM
® (versions 3.0 and 5.0, GraphPad Software, Inc.,
USA) software where Student’su n p a i r e dt-test was
employed. Statistical significance was evaluated by calcu-
lating p values. Differences where p < 0.05 were consid-
ered statistically significant. (*p < 0.05; **p < 0.01, ***p <
0.001). Densitometric analysis was carried out using
ImageJ software.
Results
P3155 was identified by us as a potent HIF-1a inhibitor
in the reporter gene based assay [11]. Specificity index
(SI) was calculated, obtained by dividing the EC50 in
U251-pGL3 by the EC50 in U251-HRE, which provides
an indication of relative specificity towards inhibition of
HIF-1 dependent transcription. P3155 had a SI of 7.1,
indicating that it had minimal or no activity on the con-
stitutive expression of luciferase in the U251-pGL3 con-
trol cell line (Figure 1, Table 1). As HIF-1a protein is
overexpressed in PC-3 prostate cancer cell line, it was
mainly used for all further studies [15].
Effect of P3155 on HIF-1a protein accumulation under
hypoxia
Studies were performed to ascertain the inhibition of
hypoxia-induced overexpression of HIF-1a protein in
the treated cell samples using western blot analysis.
P3155 showed complete abrogation of HIF-1a in PC-3
cell line and was found to inhibit hypoxia-mediated
HIF-1a protein levels in PC-3 in a dose-dependent
manner (Figure 2A).
HIF-1a inhibition by P3155 under hypoxia was
proteasome independent
HIF-1a is degraded mainly through the proteasomal
pathway. To determine whether P3155 treatment
induced degradation of HIF-1a via this pathway, we
tested the effect of P3155 in presence of 26S proteasome
inhibitor MG132 on levels of HIF-1a expression. The
level of expression of HIF-1a in the presence of
MG132/DFX was upregulated in PC-3 cells as compared
with untreated control cells. Simultaneous addition of
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Figure 1 P3155 specifically inhibits hypoxic induction of
luciferase expression in U251-HRE but not in U251-pGL3. U251-
HRE and U251-pGL3 were seeded in 96-well optiplates and
incubated under normoxic or hypoxic conditions in the presence or
absence of the indicated concentrations (μmol/L) of P3155. Cells
were treated for 24 h and then tested for luciferase expression.
Results are expressed as percentage inhibition of luciferase levels
induced under hypoxic conditions (equal to 100%). Data presented
as the average ± SE of three independent experiments.
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Page 3 of 10P3155 with MG132/DFX decreased accumulation of
HIF-1a (Figure 2B).
P3155 downregulates HIF-1a mediated VEGF expression
but does not inhibit HIF-1a mRNA levels
Increased HIF-1a expression promotes transcriptional
activation of many genes VEGF being a prime candidate.
Thus, we determined the levels of VEGF expression that
were upregulated by hypoxia-mediated HIF-1 transcrip-
tional activation. P3155 treatment significantly inhibited
DFX-stimulated levels of VEGF mRNA. As P3155 was
found to act on HIF-1a expression via proteasome-inde-
pendent pathway, the possibility of it inhibiting HIF-1a
transcription was considered. Thus, HIF-1a mRNA
levels after P3155 treatment of cells under hypoxia were
checked using RT-PCR. P3155 seemed to have no effect
on HIF-1a mRNA levels (Figure 3A).
Effect of P3155 on hypoxia-mediated accumulation of
HIF-1a and VEGF
The ability of P3155 to inhibit HIF-1a activity was
tested by evaluating levels of transcriptionally active
HIF-1a protein expressed in the nuclei of prostate can-
cer cells PC-3 and DU145 exposed to hypoxia. Treat-
ment of cells with DFX induced accumulation of active
Table 1 EC50 (μmol/L) for P3155 and topotecan
(standard) in the HIF-1a reporter gene based assay
Sr.
No.
Compound
No
EC50 (μmol/L) EC50 (μmol/L)
U251-HRE (Hypoxia/
DFX)
U251-pGL3
(normoxia)
01 P3155 1.4 > 10
02 Topotecan 0.06 > 3.0
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Figure 2 P3155 specifically inhibits HIF-1a protein accumulation under hypoxia. PC-3 cells were treated with hypoxic mimic DFX (60
μmol/L) in the presence and absence of P3155 for 8 h, and then protein extracts were prepared as described in ‘Materials and Methods’ (A)
Downregulation of HIF-1a protein by P3155 under hypoxia in a dose-dependent manner (B) P3155 inhibited hypoxia-mediated HIF-1a
accumulation in presence of DFX as well as MG132 (proteasome inhibitor) indicating that it inhibits HIF-1a independent of the proteasome
activity.
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Page 4 of 10HIF-1a protein (Figure 3B red signal) as well as its
downstream target VEGF protein (green signal) within
the nucleus. P3155 treatment induced a decrease in the
co-accumulation of active HIF-1a as well as VEGF pro-
tein under hypoxia.
P3155 inhibits HIF-1a and PI3K signaling pathway under
hypoxia
Translation of HIF-1a mRNA has been previously sug-
gested to be under the control of the phosphatidylinositol
3-kinase (PI3K) signaling pathway in various cell types
[16-18]. To test whether P3155 inhibits this pathway thus
probably leading to HIF-1a translational downregulation,
effect of P3155 on PI3K pathway was studied using PC-3
in which this pathway is constitutively active due to
PTEN mutation [19,20]. PI3K inhibition by P3155 was
seen in PC-3 cells as shown by decreased phosphoryla-
tion of the downstream targets, Akt and 4E-BP1 besides
HIF-1a under hypoxia (Figure 4).
Effect of P3155 on cancer cell migration
The hallmark of tumor cells is their ability to migrate and
metastasize. Prostate cancers are known to metastasize in
a high percentage of the cases, which is obviously linked
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Figure 3 (A) P276 specifically inhibits VEGF mRNA expression under hypoxia in a dose-dependent manner in PC-3 cells. However, HIF-
1a mRNA levels remained unchanged. (B) Inhibition of HIF-1a and VEGF expression in PC-3 and DU145 prostate cancer cells by P3155. Cells
were treated with P3155 (3 μM) for 8 h at 37°C and stained with mouse antibody against HIF-1a and rabbit antibody against VEGF. Reduced
coexpression of HIF-1a and VEGF was observed.
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Figure 4 P3155 downregulates HIF-1a expression as well as PI3K/Akt pathway under hypoxic conditions. (A) PC-3 cells were treated
with given concentrations of P3155 under hypoxia and its effect on protein levels of HIF-1a, phospho-Akt, phospho-4E-BP1 and VEGF was
determined using western blot analysis (B) densitometric analysis was carried out for each protein.
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Page 6 of 10to a poor prognosis. Therefore, potential effect of P3155
on cancer cell migration was tested using the prostate
cancer cell lines, DU145 and PC-3. The results demon-
strated that P3155 inhibited cell migration of DU145 and
PC-3 cells more than two-fold in a dose-dependent man-
ner in the presence of serum (Figure 5A).
Effect of P276 on tube formation of HUVECs
We next evaluated the effect of P3155 on the formation
of functional tubes by HUVECs plated on the Matrigel,
a reconstituted extracellular matrix preparation. Serum
was used as the stimulator in this study [21]. In the con-
trol group stimulated with serum, HUVECs rapidly
aligned with one another and formed tube-like struc-
tures resembling a capillary plexus within 24 h, which
required cell-matrix interaction, intercellular interaction
and cell motility. P3155 prevented serum-stimulated
tube formation of HUVECs in a dose-dependent manner
and no cytotoxicity was observed at these particular
concentrations (Figure 5B). At the same timepoint and
concentrations, P3155 downregulated phospho-Akt (Ser
473) levels in a dose-dependent and significant manner
(Figure 5B).
Effect of P3155 on tumor growth in vivo
Because of the observed in vitro effects of P3155, we
investigated whether it inhibits tumor growth in vivo.
To confirm the in vivo activity of P3155, antitumor effi-
c a c yo fP 3 1 5 5i nx e n o g r a f tm o d e lo fP C - 3w a ss t u d i e d .
The average tumor weights on day 20 for control and
P3155 were 933 ± 285.6 mg and 358.6 ± 143.9 mg
respectively and the calculated highest percentage of
growth inhibition was observed to be 61% on day 9 after
randomization (Figure 6, p < 0.05). Mice treated with
P3155 had no significant weight loss while on the study
drug (data not shown). These results indicate that
P3155 effectively inhibits tumor growth in tumor bear-
ing mice.
Discussion
Overexpression of HIF-1a is a common feature of solid
malignancies and is correlated with advanced disease
stage, increased angiogenesis and poor prognosis [21].
HIF-1 induces expression of genes whose products are
involved in cancer cells’ survival, glycolysis, angiogenesis,
migration and invasion [22]. As a result, HIF-1 has
emerged as an attractive molecular target for the devel-
opment of novel cancer therapeutics. P3155 was identi-
fied as a potent and specific inhibitor of HIF-1
transcriptional activation in the reporter gene-based
assay. Genetic features of PC-3 prostate cancer cells
such as loss of PTEN, constitutive activation of PI3K/
Akt pathway, overexpression of HIF-1a,p 5 3n e g a t i v i t y
make them an attractive model for studying the mode
of action of HIF-1a inhibitors and they have been
employed by several groups for such studies earlier
[23-25]. Hence, we selected PC-3 cells to elucidate the
mechanism of action of P3155 under hypoxia. Since
the HIF-1 pathway can be inhibited at several different
points, including post-translational modification, gene
transcription, or protein translation, next we investi-
gated whether P3155 had any effect on proteasomal
degradation of HIF-1a protein, or synthesis of its
mRNA or protein. We found that HIF-1a protein
downregulation by P3155 is independent of the ubiqui-
tin-proteasomal pathway as blocking P3155-induced
HIF-1a protein degradation with the proteasome inhi-
bitor MG132 failed to restore HIF-1a protein expres-
sion (Figure 2B). Also our present results indicate that
P3155 induced degradation of HIF-1a p r o t e i ni na
dose-dependent manner with no effect on HIF-1a
mRNA levels (Figure 3A). Possibility of inhibition of
HIF-1a by P3155 at the translational level was there-
fore considered.
It was previously shown that HIF-1a protein could be
stimulated by serum and other growth factors via the
phosphotidyl-3-kinase pathway [26]. The PI3K/Akt
pathway is activated by hypoxia in certain cell types and
interference with the Akt reduces accumulation of HIF
in response to hypoxia [27]. This pathway also plays a
key role in the control of HIF-1a translation and synth-
esis in prostate cancer cells. Inhibition of coexpression
of HIF-1a and VEGF was observed by immunofluores-
cence in PC-3 and DU145 prostate cancer cells (Figure
3B). Treatment of hypoxic PC-3 cells with P3155
resulted in reduced HIF-1a expression as well as
decreased phosphorylation of Akt and its downstream
effector 4E-BP1, which controls the initiation of protein
translation under hypoxia [28] in a dose-dependent
manner (Figure 4). These observations support the
hypothesis that PI3K/Akt pathway could be involved in
P3155-mediated HIF-1a inhibition by inhibition of its
translation.
Abrogation of HIF-1a and VEGF expression by P3155
was demonstrated by immunofluorescence. In the past
few years the field of siRNAs has emerged at a surpris-
ingly high pace. In the present study, we found that
P3155 was as effective as HIF-1a siRNA in HIF-1a sup-
pression. Upon transfection with si-RNA, there was
dose-dependent inhibition of HIF-1a at the protein level
(Additional file 1, Figure S1). It was evident that subop-
timal doses of both si-RNA and P3155 resulted in com-
plete abrogation of HIF-1a thus exhibiting synergism.
Tumor invasion and metastasis are essential for tumor
growth and are also directly regulated by HIF-1a.
Wound healing assays are a classic and commonly used
method for studying cell migration and the biology
underlying it. The assay has been used for studying cell
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Figure 5 ( A )E f f e c to fP 3 1 5 5o nP C - 3a n dD U - 1 4 5c e l lm i g r a t i o n( B) Effect of P3155 on HUVEC tube formation (C) P3155
downregulates PI3K/Akt pathway as evident by inhibition of phospho-Akt (Ser 473) levels in HUVECs at the same concentrations and
timepoint.
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Page 8 of 10polarization, matrix remodeling, cell migration as well as
a proxy for angiogenesis, metastasis [29]. This assay was
employed to assess the anti-migratory potential of
P3155. Prostate cancer cells were selected for this study
because of their invasiveness in vitro.A ss h o w ni nF i g -
ure 5a, P3155 potently inhibited wound healing of these
cells and no toxicity was observed. One of the most
widely used in vitro assays to model the reorganization
stage of angiogenesis is the tube formation assay. The
assay measures the ability of endothelial cells, plated at
subconfluent densities with the appropriate extracellular
matrix support, to form capillary-like structures [30,31].
P3155 effectively blocked tube formation by HUVEC
cells as shown in Figure 5b in a dose-dependent man-
ner. It also inhibited PI3K/Akt pathway which was evi-
dent by decreased phospho-AktSer473 levels. Taken
together, these results suggest that P3155 inhibits cell
migration and angiogenesis via inhibition of HIF-1a and
PI3K/Akt pathway.
A number of anti-cancer agents have been reported to
decrease HIF-1a activity in cells in culture however,
only a few of the reported HIF-1a inhibitors demon-
strated antitumor activity in vivo [32,8]. Because of pro-
mising in vitro results of our identified HIF-1a
inhibitor, we examined tumor growth inhibition due to
P3155 treatment. The human xenograft model showed
efficacy of P3155 in prostate cancer when given by p.o.
route. It showed significant anti-tumor activity with 61%
growth inhibition. These results suggest that P3155 is
an inhibitor of HIF-1 that halts tumor growth by
blocking tumor adaptation to hypoxia and thus can be
used as a therapeutic modality for aggressive prostate
cancer.
Conclusion
In summary, we conclude from these studies that P3155
is a specific inhibitor of HIF-1a and it also abrogates
PI3K pathway. We confirmed the inhibitory effects of
P3155 on expression of HIF-1a and on the induction of
VEGF under hypoxia by western blot analysis and
immunofluorescence. It showed significant antiangio-
genic potential on prostate cancer cells and in vivo,
treatment with P3155 halted the growth of xenograft
tumor originating from PC-3 cells.
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model. Mice were treated with daily p.o. doses of P3155 at 50 mpk
for 20 days. Percentage tumor weight profile during the course of
treatment.
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